Emergence of small molecule non-RGD-mimetic inhibitors for RGD integrins

Lisa M. Miller, John M. Pritchard, Simon J. F. Macdonald, Craig Jamieson, Allan J. B. Watson

Research output: Contribution to journalArticle

20 Citations (Scopus)
71 Downloads (Pure)

Abstract

The RGD integrins are recognized therapeutic targets for thrombosis, fibrosis, and cancer, amongst others. Current inhibitors are designed to mimic the tripeptide sequence (arginineglycine-aspartic acid) of the natural ligands; however, the RGD-mimetic antagonists for αIIbβ3 have been shown to cause partial agonism, leading to the opposite pharmacological effect. The challenge of obtaining oral activity and synthetic tractability with RGD-mimetic molecules, along with the issues relating to pharmacology, has left integrin-therapeutics in need of a new strategy. Recently, a new generation of inhibitor has emerged that lacks the RGD-mimetic. This 2 perspective will discuss the discovery of these non-RGD-mimetic inhibitors, and the progress that has been made in this promising new chemotype.
Original languageEnglish
Number of pages11
JournalJournal of Medicinal Chemistry
Volume60
Issue number8
Early online date30 Jan 2017
DOIs
Publication statusPublished - 30 Jan 2017

Fingerprint

Integrins
Pharmacology
Molecules
Aspartic Acid
Thrombosis
Fibrosis
Ligands
Therapeutics
Neoplasms

Keywords

  • RGD integrins
  • therapeutic targets
  • tripeptide sequence
  • ligands
  • non-RGD-mimetic inhibitors
  • heterodimeric cell adhesion receptors
  • extracellular matrix

Cite this

Miller, Lisa M. ; Pritchard, John M. ; Macdonald, Simon J. F. ; Jamieson, Craig ; Watson, Allan J. B. / Emergence of small molecule non-RGD-mimetic inhibitors for RGD integrins. In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 8.
@article{60ed3731bcdf4dc792b8f0487f0567b6,
title = "Emergence of small molecule non-RGD-mimetic inhibitors for RGD integrins",
abstract = "The RGD integrins are recognized therapeutic targets for thrombosis, fibrosis, and cancer, amongst others. Current inhibitors are designed to mimic the tripeptide sequence (arginineglycine-aspartic acid) of the natural ligands; however, the RGD-mimetic antagonists for αIIbβ3 have been shown to cause partial agonism, leading to the opposite pharmacological effect. The challenge of obtaining oral activity and synthetic tractability with RGD-mimetic molecules, along with the issues relating to pharmacology, has left integrin-therapeutics in need of a new strategy. Recently, a new generation of inhibitor has emerged that lacks the RGD-mimetic. This 2 perspective will discuss the discovery of these non-RGD-mimetic inhibitors, and the progress that has been made in this promising new chemotype.",
keywords = "RGD integrins, therapeutic targets , tripeptide sequence, ligands, non-RGD-mimetic inhibitors, heterodimeric cell adhesion receptors, extracellular matrix",
author = "Miller, {Lisa M.} and Pritchard, {John M.} and Macdonald, {Simon J. F.} and Craig Jamieson and Watson, {Allan J. B.}",
note = "This document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Medicinal Chemistry, copyright {\circledC} American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acs.jmedchem.6b01711",
year = "2017",
month = "1",
day = "30",
doi = "10.1021/acs.jmedchem.6b01711",
language = "English",
volume = "60",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "8",

}

Emergence of small molecule non-RGD-mimetic inhibitors for RGD integrins. / Miller, Lisa M.; Pritchard, John M.; Macdonald, Simon J. F.; Jamieson, Craig; Watson, Allan J. B.

In: Journal of Medicinal Chemistry, Vol. 60, No. 8, 30.01.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Emergence of small molecule non-RGD-mimetic inhibitors for RGD integrins

AU - Miller, Lisa M.

AU - Pritchard, John M.

AU - Macdonald, Simon J. F.

AU - Jamieson, Craig

AU - Watson, Allan J. B.

N1 - This document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Medicinal Chemistry, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acs.jmedchem.6b01711

PY - 2017/1/30

Y1 - 2017/1/30

N2 - The RGD integrins are recognized therapeutic targets for thrombosis, fibrosis, and cancer, amongst others. Current inhibitors are designed to mimic the tripeptide sequence (arginineglycine-aspartic acid) of the natural ligands; however, the RGD-mimetic antagonists for αIIbβ3 have been shown to cause partial agonism, leading to the opposite pharmacological effect. The challenge of obtaining oral activity and synthetic tractability with RGD-mimetic molecules, along with the issues relating to pharmacology, has left integrin-therapeutics in need of a new strategy. Recently, a new generation of inhibitor has emerged that lacks the RGD-mimetic. This 2 perspective will discuss the discovery of these non-RGD-mimetic inhibitors, and the progress that has been made in this promising new chemotype.

AB - The RGD integrins are recognized therapeutic targets for thrombosis, fibrosis, and cancer, amongst others. Current inhibitors are designed to mimic the tripeptide sequence (arginineglycine-aspartic acid) of the natural ligands; however, the RGD-mimetic antagonists for αIIbβ3 have been shown to cause partial agonism, leading to the opposite pharmacological effect. The challenge of obtaining oral activity and synthetic tractability with RGD-mimetic molecules, along with the issues relating to pharmacology, has left integrin-therapeutics in need of a new strategy. Recently, a new generation of inhibitor has emerged that lacks the RGD-mimetic. This 2 perspective will discuss the discovery of these non-RGD-mimetic inhibitors, and the progress that has been made in this promising new chemotype.

KW - RGD integrins

KW - therapeutic targets

KW - tripeptide sequence

KW - ligands

KW - non-RGD-mimetic inhibitors

KW - heterodimeric cell adhesion receptors

KW - extracellular matrix

UR - http://pubs.acs.org/journal/jmcmar

U2 - 10.1021/acs.jmedchem.6b01711

DO - 10.1021/acs.jmedchem.6b01711

M3 - Article

VL - 60

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 8

ER -